An outer membrane vesicle vaccine for prevention of serogroup A and W-135 meningococcal disease in the African meningitis belt

Scandinavian Journal of Immunology

Volumn 76, Issue 2, 2012, Pages 99-107

  Norheim, G ^a   Tunheim, G ^a   Naess L M ^a   Kristiansen, P A ^a   Caugant, D A ^a,b   Rosenqvist, E ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; IMMUNOGLOBULIN G ANTIBODY; MENINGITIS VACCINE; OUTER MEMBRANE VESICLE VACCINE; UNCLASSIFIED DRUG;

AFRICA; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC MENINGITIS; FEMALE; HUMAN; IMMUNOBLOTTING; IMMUNOGENICITY; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SERUM BACTERICIDAL ACTIVITY;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; MENINGITIS, MENINGOCOCCAL; MICE; NEISSERIA MENINGITIDIS, SEROGROUP A; NEISSERIA MENINGITIDIS, SEROGROUP W-135;

EID: 84864311423     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2012.02709.x     Document Type: Article

References (57)

1. Lapeyssonnie L. [Cerebrospinal meningitis in Africa]. Bull World Health Organ 1963;28 (Suppl):1-114.
2. Molesworth AM, Thomson MC, Connor SJ et al. Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa. Trans R Soc Trop Med Hyg 2002;96:242-9.
3. LaForce M, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009;27 Suppl 2:B13-9.
4. Achtman M, Kusecek B, Morelli G et al. A comparison of the variable antigens expressed by clone IV-1 and subgroup III of Neisseria meningitidis serogroup A. J Infect Dis 1992;165:53-68.
5. Maiden MC, Bygraves JA, Feil E et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 1998;95:3140-5.
6. Caugant DA, Nicolas P. Molecular surveillance of meningococcal meningitis in Africa. Vaccine 2007;25 Suppl 1:A8-11.
7. Nicolas P, Decousset L, Riglet V, Castelli P, Stor R, Blanchet G. Clonal expansion of sequence type (ST-)5 and emergence of ST-7 in serogroup A meningococci, Africa. Emerg Infect Dis 2001;7:849-54.
8. Sie A, Pfluger V, Coulibaly B et al. ST2859 serogroup A meningococcal meningitis outbreak in Nouna Health District, Burkina Faso: a prospective study. Trop Med Int Health 2008;13:861-8.
9. Norheim G, Rosenqvist E, Hoiby EA, Caugant DA. Comparison of serogrop A Neisseria meningitidis strains of sequence type 2859 emerging in Burkina Faso in meningitis seasons 2003 and 2004 with predominating ST-7 strains [abstract] 16th International Pathogenic Neisseria Conference 7-12 September. Rotterdam, the Netherlands 2008.
10. Koumare B, Ouedraogo-Traore R, Sanou I et al. The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine 2007;25 Suppl 1:A37-41.
11. WHO 2005. Global Alert and Response (GAR).
12. Achtman M. Global epidemiology of meningococcal disease. Cartwright K, ed. Meningococcal Disease. Chichester: John Wiley & Sons Ltd, 1995:159-75.
13. Delrieu I, Yaro S, Tamekloe TA et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS ONE 2011;6:e19513.
14. LaForce M, Konde K, Viviani S, Preziosi MP. The Meningitis Vaccine Project. Vaccine 2007;25 Suppl 1:A97-100.
15. Sow SO, Okoko BJ, Diallo A et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011;364:2293-304.
16. WHO. Meningitis Weekly Bulletin Week 31-34, 2011 West Africa. WHO 2011
17. Amir J, Louie L, Granoff DM. Naturally-acquired immunity to Neisseria meningitidis group A. Vaccine 2005;23:977-83.
18. Norheim G, Aseffa A, Yassin MA et al. Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci. Clin Vaccine Immunol 2008;15:863-71.
19. Norheim G, Aseffa A, Yassin MA et al. Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7. Clin Vaccine Immunol 2007;14:451-63.
20. Arnold R, Galloway Y, McNicholas A, O'Hallahan J. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine 2011;29:7100-6.
21. Caron F, du Chatelet IP, Leroy JP et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis 2011;11:455-63.
22. Bjune G, Hoiby EA, Gronnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991;338:1093-6.
23. Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999;281:1520-7.
24. Holst J, Feiring B, Fuglesang JE et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003;21:734-7.
25. Rosenqvist E, Hoiby EA, Wedege E et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 1995;63:4642-52.
26. Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006;103:10834-9.
27. Norheim G, Hoiby EA, Caugant DA et al. Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease. Vaccine 2004;22:2171-80.
28. Holst J, Martin D, Arnold R et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009;27 Suppl 2:B3-12.
29. Findlow J, Borrow R, Snape MD et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010;51:1127-37.
30. Norheim G, Aase A, Caugant DA et al. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. Vaccine 2005;23:3762-74.
31. Norheim G, Rosenqvist E, Aseffa A et al. Characterization of Neisseria meningitidis isolates from recent outbreaks in Ethiopia and comparison with those recovered during the epidemic of 1988 to 1989. J Clin Microbiol 2006;44:861-71.
32. Russell JE, Jolley KA, Feavers IM, Maiden MC, Suker J. PorA variable regions of Neisseria meningitidis. Emerg Infect Dis 2004;10:674-8.
33. Thompson EA, Feavers IM, Maiden MC. Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 2003;149:1849-58.
34. Comanducci M, Bambini S, Brunelli B et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002;195:1445-54.
35. Comanducci M, Bambini S, Caugant DA et al. NadA diversity and carriage in Neisseria meningitidis. Infect Immun 2004;72:4217-23.
36. Jacobsson S, Thulin S, Molling P et al. Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine 2006;24:2161-8.
37. Murphy E, Andrew L, Lee KL et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009;200:379-89.
38. Fu J, Bailey FJ, King JJ et al. Recent advances in the large scale fermentation of Neisseria meningitidis group B for the production of an outer membrane protein complex. Biotechnology (N Y) 1995;13:170-4.
39. Rosenqvist E, Musacchio A, Aase A et al. Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis. Infect Immun 1999;67:1267-76.
40. Tsai CM, Frasch CE, Rivera E, Hochstein HD. Measurements of lipopolysaccharide (endotoxin) in meningococcal protein and polysaccharide preparations for vaccine usage. J Biol Stand 1989;17:249-58.
41. Wedege E. Immunoblot analysis of sera from patients and vaccinees. Pollard AJ, Maiden MC, eds. Meningococcal Vaccines: Methods and Protocols. Totowa, NJ: Human Press Inc, 2001:275-88.
42. Maslanka SE, Gheesling LL, Libutti DE et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 1997;4:156-67.
43. Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis 2009;199:1360-8.
44. Fredriksen JH, Rosenqvist E, Wedege E et al. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 1991;14:67-79.
45. Wedege E, Froholm LO. Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect Immun 1986;51:571-8.
46. Wright JC, Williams JN, Christodoulides M, Heckels JE. Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis. Infect Immun 2002;70:4028-34.
47. Saukkonen K, Abdillahi H, Poolman JT, Leinonen M. Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development. Microb Pathog 1987;3:261-7.
48. Michaelsen TE, Aase A, Kolberg J, Wedege E, Rosenqvist E. PorB3 outer membrane protein on Neisseria meningitidis is poorly accessible for antibody binding on live bacteria. Vaccine 2001;19:1526-33.
49. Sandbu S, Feiring B, Oster P et al. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines. Clin Vaccine Immunol 2007;14:1062-9.
50. Claassen I, Meylis J, van der LP et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 1996;14:1001-8.
51. Luijkx T, van DH, van EC, van den Dobbelsteen G. Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine. Vaccine 2006;24:1569-77.
52. Cartwright K, Morris R, Rumke H et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 1999;17:2612-9.
53. Boutriau D, Poolman J, Borrow R et al. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19, 15 and B:4:p1.7-2, 4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin Vaccine Immunol 2007;14:65-73.
54. Snape MD, Dawson T, Oster P et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010;29:e71-9.
55. Achtman M. Epidemic spread and antigenic variability of Neisseria meningitidis. Trends Microbiol 1995;3:186-92.
56. Suker J, Feavers IM, Achtman M, Morelli G, Wang JF, Maiden MC. The porA gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation. Mol Microbiol 1994;12:253-65.
57. Nicolas P, Norheim G, Garnotel E, Djibo S, Caugant DA. Molecular epidemiology of Neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol 2005;43:5129-35.